About FDA

Division of Anesthesia, Analgesia, and Addiction Products (DAAAP)

Division Director: Bob A. Rappaport, M.D. 
Deputy Directors: Sharon Hertz, M.D., and Rigoberto Roca, M.D. 
Deputy Director for Safety: Judith Racoosin, M.D., M.P.H 
Associate Director for Special Projects: Allison Lin, Ph.D., Pharm.D. 
Chiefs, Project Management Staff: Parinda Jani and Matthew Sullivan 
Safety Regulatory Project Manager: Mark Liberatore
 
The Division of Anesthesia, Analgesia, and Addiction Products regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics Licensing Applications (BLAs) for prescription drugs and biologics intended for the prevention, treatment, or diagnosis of conditions including:
  • Acute Pain, e.g.:
    • Surgical and procedural pain
    • Pain due to trauma/injury
    • Pain due to acute inflammatory processes
  • Chronic pain, e.g.:
    • Cancer pain
    • Neuropathic pain
    • Fibromyalgia
    • Osteoarthritis Pain
    • Low back pain
  • Addiction, e.g.:
    • Nicotine
    • Alcohol
    • Stimulants
    • Opioids
DAAAP also regulates the drug product classes that are used in surgical, procedural or ICU settings to provide patient comfort and/or ease of treatment, e.g.:
  • General anesthetics
  • Local anesthetics
  • Dental anesthetics
  • Topical anesthetics
  • Neuromuscular-blocking agents and neuromuscular-blocker reversal agents
Mailing Address:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Anesthesia, Analgesia, and Addiction Products
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-2280
Fax: (301) 796-9723

 

 

Page Last Updated: 12/10/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.